Chris Boshoff: Science Will Win Against Multiple Myeloma
In a post on LinkedIn by Chris Boshoff, Chief Oncology Research and Development Officer and Executive Vice President at Pfizer, it says:
“About half of the 176,000 people around the world who are diagnosed with Multiple Myeloma each year won’t survive past the next five, and most will receive four or more lines of therapy due to relapse and resistance. There is a tremendous unmet need for new treatment options for this devastating blood cancer, which currently has no cure.
Today, I am #PfizerProud to share that the FDA has approved our innovative new targeted immunotherapy in multiple myeloma, which builds upon scientific insights in tumor immunology to mobilize the patient’s immune system against their cancer.”
Read more here and at the link below: Science Will Win Against Multiple Myeloma
Source: Chris Boshoff / LinkedIn
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023